Marc Sitbon is a MUSE laureate for TheranosMet.
TheranosMet is one of the 8 laureates in Biology & Health of the first call for research projects by MUSE (Montpellier Université d’Excellence). The 3-year MUSE program includes support for a PhD student. TheranosMet focuses on the theranostic use of RBD nanoparticles. RBDs are Receptor-Binding Domains derived from retroviruses that target nutrient transporters. RBDs that bind transporters known to play … Continue reading Marc Sitbon is a MUSE laureate for TheranosMet.